Black Diamond Therapeutics (BDTX) PT Raised to $44 at JPMorgan, Following Earnings
- Dow hits milestone, S&P breaks record high on tech rally
- Thermo Fisher Scientific (TMO) to Acquire PPD, Inc. (PPD) for $47.50/sh, $17.4 Billion
- U.S. retail sales post largest gain in 10 months; weekly jobless claims fall
- The Stock Market is Almost 'Completely Broken' - Einhorn
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
JPMorgan analyst Eric Joseph raised the price target on Black Diamond Therapeutics (NASDAQ: BDTX) to $44.00 (from $43.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: UBS Upgrades JinkoSolar Holding Co., Ltd. (JKS) to Neutral
- Pendal Group Ltd (PDL:AU) PT Raised to AUD7.81 at Goldman Sachs
- Bank of Queensland Ltd. (BOQ:AU) (BKQNY) PT Raised to AUD10 at Credit Suisse